Dehydroepiandrosterone supplementation in assisted reproduction: rationale and results.
OBJECTIVE
To present the possible positive effect of dehydroepiandrosterone administration in assisted reproduction and especially in poor responders, women with diminished ovarian reserve, premature ovarian failure and premature ovarian aging in the course of ovarian stimulation protocols followed either by intrauterine insemination or IVF.


RESULTS
Overall, 50-75 mg of dehydroepiandrosterone supplementation for at least 4 months may either result in natural conception or considerably improves intrauterine insemination and IVF outcome and pregnancy rates to women with confirmed diminished ovarian reserve, premature ovarian failure or premature ovarian aging. Positive effect has been reported to oocyte and embryo quality, even to women aged 40-47 years. The number of euploid embryos is increased, and miscarriage rate is decreased.


CONCLUSIONS
Although more data on the dehydroepiandrosterone effect on assisted reproduction are needed, results obtained over the last few years confirm the improvement of oocyte production and pregnancy rates. No significant side effects are reported, and those include mainly hirstusism and acne.
Mamas
Leonidas
L
3 Kifissias Av., Marousi 15123, Athens, Greece. leonidasmamas@neogenesis.gr
Mamas
Eudoxia
E
D000367:Age Factors; D000375:Aging / Q000502:physiology; D003687:Dehydroepiandrosterone / Q000009:adverse effects / Q000494:pharmacology*; D005260:Female; D005300:Fertility Agents, Female / Q000009:adverse effects / Q000494:pharmacology*; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy*; D010062:Ovulation Induction; D011247:Pregnancy; D018873:Pregnancy Rate; D016649:Primary Ovarian Insufficiency / Q000188:drug therapy; D027724:Reproductive Techniques, Assisted; D016896:Treatment Outcome
D005300:Fertility Agents, Female; D003687:Dehydroepiandrosterone